Melanoma has been one ofthe fastest rising malignancies in the last four decades with cases increasing from below three per 100,000 people to above 13 (18.9 if only whites are counted). The following discoveries have been made that serve as the basis for this program project: 1) Mutations in genes ofthe MAP kinase pathway are frequent in melanoma and mutually exclusive. Mutations are most frequent in BRAF (50%) followed by NRAS (15%) and c-kit (4%). 2) Within each mutation group there are sub-groups due to additional critical mutations. 3) The biological characteristics of melanomas including their progression and metastasis are driven by both tumor and microenvironment forces. 4) Small molecule inhibitors for tumor-associated kinases lead to powerful effects on melanoma cells both in vitro and in vivo. Our first objective is to identify somatic alterations in growth factor mediated signaling pathways and determine whether they are targets for therapy. Our group (Project 2, Bastian) has recently identified c-kit mutations in melanoma, particularly in acral and mucosal melanomas, that are mutually exclusive to BRAF and NRAS mutations, and emerging trial data suggest that drugs targeting c-kit induce significant clinical responses in some patients with these mutations. Several lines of evidence point towards a wider role ofthe c-kit signaling pathway is specific types of melanoma and we will perform detailed genetic and functional analyses to analyze the pathway for additional therapeutic targets and factors of primary and secondary resistance to ckit directed therapies (Project 2, Bastian). Two other genes that function downstream of c-kit encoding isoforms of the p70S6 kinase, critical regulators of protein synthesis and cell growth, are also amplified in many melanomas. Therefore, we will characterize the biochemical properties of p70S6K and develop potent and specific inhibitors to this kinase (Project 3, Marmorstein). Our complementary second objective that focuses on therapy resistance in melanoma is to identify sub-populations of tumor cells that are drivers for tumor progression and evaluate combination therapeutic strategies that target this tumor cell sub-population in addition to the bulk of tumor cells. Our group (Project 1, Herlyn) has identified melanoma cells with high self-renewing capacity that are very slowly cycling but have a high proliferative reserve. They are characterized by expression ofthe histone 3 K4 demethylase JARID1B. In this proposal we will characterize the signaling mechanisms mediating therapy resistance in JARID1B+ cells and biochemically analyze the JARID1B protein to develop and evaluate therapeutic strategies using inhibitors to JARID1B and/or JARIDIB-dependant signaling (Project 3, Marmorstein and Project 1, Herlyn).

Public Health Relevance

The major objective of this long-standing program project is to better understand the biology of melanoma development from a normal melanocytes to a mole and the progression to primary and metastatic melanoma. In the past, we have delineated each progression stage with monoclonal antibodies and have developed models in culture and experimental animals that mimic the disease as we experience it in patients. In this renewal application we continue to work on the biology of melanoma with a major emphasis on using the accumulated information to develop new strategies for therapy. Forthis reason, we have expanded the project, which includes now a structural biologist and a chemist to develop inhibitors for two key enzymes for this malignancy. This multi-disciplinary program has been a long-term center for novel approaches in melanoma research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA025874-32
Application #
8450867
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (J1))
Program Officer
Sathyamoorthy, Neeraja
Project Start
1990-04-06
Project End
2016-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
32
Fiscal Year
2013
Total Cost
$1,352,759
Indirect Cost
$301,754
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Talevich, Eric; Shain, A Hunter; Botton, Thomas et al. (2016) CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol 12:e1004873
Lu, Hezhe; Liu, Shujing; Zhang, Gao et al. (2016) Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep 15:2012-24
Krepler, Clemens; Xiao, Min; Samanta, Minu et al. (2016) Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget :
Shannan, Batool; Chen, Quan; Watters, Andrea et al. (2016) Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment Cell Melanoma Res 29:317-28
Krepler, Clemens; Xiao, Min; Sproesser, Katrin et al. (2016) Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res 22:1592-602
Yeh, Iwei; Tee, Meng Kian; Botton, Thomas et al. (2016) NTRK3 kinase fusions in Spitz tumours. J Pathol 240:282-290
Shannan, Batool; Perego, Michela; Somasundaram, Rajasekharan et al. (2016) Heterogeneity in Melanoma. Cancer Treat Res 167:1-15
Cierlitza, Monika; Chauvistré, Heike; Bogeski, Ivan et al. (2015) Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. Exp Dermatol 24:155-7
Qin, Jie; Rajaratnam, Rajathees; Feng, Li et al. (2015) Development of organometallic S6K1 inhibitors. J Med Chem 58:305-14
Carvajal, Richard D; Lawrence, Donald P; Weber, Jeffrey S et al. (2015) Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res 21:2289-96

Showing the most recent 10 out of 366 publications